Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Vesugen vs Crystagen

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Vesugen and Crystagen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Vesugen

Russian Research

Crystagen

Russian Research

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: limited western evidence. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Vesugen Crystagen
Class Khavinson short peptide bioregulator Khavinson short peptide bioregulator
Drug class Tissue Repair Immune
Mechanism Endothelial gene expression modulation Tissue-specific gene expression in lymphoid/thymic cells; normalizes T-cell and macrophage activity; doubles HSPA1A heat-shock expression and modulates IL-6
Route Oral Oral
Half-life Short (minutes) Short (minutes)
Dosage (research) Oral capsule 1-2x daily Oral 1-2 capsules daily for 20-30 day courses
Evidence tier Russian Research Russian Research
Research depth 10 indexed (PubMed 6 · CT 0 · EPMC 4) 36 indexed (PubMed 35 · CT 0 · EPMC 1)
Availability Research Research
Reported risks Limited Western evidence Limited Western evidence; primarily Russian gerontology literature

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Vesugen or Crystagen?

Vesugen and Crystagen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.

What is the difference between Vesugen and Crystagen?

Vesugen is classed as Khavinson short peptide bioregulator; Crystagen is classed as Khavinson short peptide bioregulator. Reported mechanism: Vesugen, Endothelial gene expression modulation; Crystagen, Tissue-specific gene expression in lymphoid/thymic cells; normalizes T-cell and macrophage activity; doubles HSPA1A heat-shock expression and modulates IL-6. Reported half-life: Vesugen, Short (minutes); Crystagen, Short (minutes). Routes in published studies: Vesugen, Oral; Crystagen, Oral.

Which has stronger evidence, Vesugen or Crystagen?

Vesugen and Crystagen sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Vesugen is graded Russian Research, with 2 cited sources on its reference page and 10 indexed studies. Crystagen is graded Russian Research, with 2 cited sources on its reference page and 36 indexed studies.

Which is more accessible, Vesugen or Crystagen?

Neither Vesugen nor Crystagen is an FDA-approved drug. Catalog status: Vesugen, Research; Crystagen, Research.

Are Vesugen and Crystagen ever combined?

Vesugen and Crystagen appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…